| (Values in U.S. Thousands) | Jun, 2020 | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 |
| Sales | 11,690 | 1,750 | 0 | 0 | 0 |
| Sales Growth | +568.00% | unch | unch | unch | unch |
| Net Income | -167,440 | -40,230 | -21,500 | -16,860 | -16,480 |
| Net Income Growth | -316.21% | -87.12% | -27.52% | -2.31% | +12.67% |
Menlo Therapeutics Inc (MNLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California.